首页> 外文期刊>中国神经再生研究(英文版) >Comparisons of drug efficacy and time-effect among magnesium valproate,sustained-release magnesium valproate tablet and depakine chrono for epilepsy An experiment of determining cortical convulsive threshold in rats undergoing electrical stimulation
【24h】

Comparisons of drug efficacy and time-effect among magnesium valproate,sustained-release magnesium valproate tablet and depakine chrono for epilepsy An experiment of determining cortical convulsive threshold in rats undergoing electrical stimulation

机译:丙戊酸镁,缓释丙戊酸镁片和地卡帕因chrono用于癫痫的药效和时效比较测定电刺激大鼠皮层惊厥阈的实验

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND:Scholars have investigated the differences in drug metabolism and pharmacodynamics between valproate and its sustained-release tablets only from the angle of pharmaceutical sciences or clinical practice.Whether the fact that differences in drug efficacy and time-effect of different doses of valproate and different types of sustained-release valproate tablets at the same concentration can be quantitatively reflected by determining the changes in convulsive threshold pre- and post-administration in rat models of determining the convulsive threshold developed by direct cortical electrical stimulation remains unclear.OBJECTIVE:This study aimed to compare the drug efficacy and time-effect among magnesium valproate,sustained-release magnesium valproate tablet and depakine chrono in the treatment of epilepsy by determining the convulsive threshold of rat models created by direct cortical electrical stimulation,and human serum drug concentration before and after administration.DESIGN:A controlled observational experiment.SETTING:Research Institute of Epilepsy,Shanxi Medical University.MATERIALS:Adult health male SD rats of clean grade,weighing 200 - 220 g,provided by the Laboratory Animal Center of Shanxi Medical University.The protocol was carried out in accordance with requests from Animal Ethics Committees for guidance.Magnesium valproate (Lot No.041004) and sustained-release magnesium valproate tablet (Lot No.050501) were produced in Hunan Xiangzhong Pharmaceutical Co.,Ltd.METHODS:This study was carried out in the Laboratory for Epilepsy,Shanxi Medical University between June and August 2005.①All the SD rats were created into models for determining cortical convulsive threshold.They were randomly divided into 4 groups with 20 rats in each:magnesium valproate tablet group,sustained-release magnesium valproate tablet group,depakine chrono group and control group.After being modeled,the rats in the first 3 groups were intragastrically administrated with magnesium valproate,sustained-release magnesium valproate tablet and depakine chrono,respectively,while the control group were intragastrically administrated with the same volume of normal saline.②Convulsive threshold of each fasting rat was determined 0.5 hour before,and 0.5,1,2,3,4,5,6,7,8,9,10,12,14and24 hours after single administration,separately.③Convulsive threshold was determined repeatedly 2 weeks after single administration.Each rat was administrated two times daily successively.Convulsive threshold was determined 0.5 hour before,and 0.5,2.5,7and12hours after administration,separately.④Hepatic and renal tissues were harvested for pathological examination after 1 month of administration.⑤Nine healthy voluntary medical stuffs were recruited in this study.Written informed consents of experiment were obtained each involved subject.The study was given an approval by the Ethics Committee of Shanxi Medical University.According to the scheme,the 9 volunteers were randomly assigned into 3 groups,in which,volunteers were asked to take magnesium valproate 500 g,sustained-release magnesium valproate tablet 500 g and depakine chrono 500g,respectively,in the morning under the condition of fasting.Serum drug concentration of each drug was determined by fluorescence polarization immunoassay at different time points.MAIN OUTCOME MEASURES:①Rat convulsive threshold after single and repeated administrations.②Hepatic and renal pathological examination results.③Serum drug concentration in vivo.RESULTS:①Rat convulsive threshold after single and repeated administrations:Drug efficacy in the magnesium valproate tablet group reached to a peak level 1 to 2 hours after single administration,and was obviously higher than that in the other groups 1 hour after administration (P<0.05).Drug efficacy in the sustained-release magnesium valproate tablet group and depakine chrono group both reached to a peak level 7 hours after administration,and was significantly higher than that in the control group (P<0.05).After repeated administrations,the average peak valley deviation of the convulsive threshold in the magnesium valproate tablet group was 120-150 Μa,which was 2 and 2.5 times as that in the sustained-release magnesium valproate tablet group and depakine chrono group,respectively.After repeated administrations for 10 times,convulsive threshold was increased by 440 Μa in the sustained-release magnesium valproate tablet group,and by 230 μ A in the depakine chrono group in comparison with before administration.② Hepatic and renal pathological examination results:No obvious differences in hepatic and renal impairment were found among the 4 groups after 1 month of administration successively.③ Serum drug concentration in vivo:Serum-drug concentration of magnesium valproate was increased fast and reached to a peak level 0.5-2 hours after administration,remained at a relatively stable level 2-4 hours after administration,and then was slowly decreased.The drug efficacy of sustained-release magnesium valproate tablet and depakine chrono was slowly released 1-6 hours after administration,reached to a peak level at about 7 hours,and could last for about 16 hours.CONCLUSION:Magnesium valproate has a rapid onset and offset of action.Sustained-release magnesium valproate tablet has a slow onset but long duration of drug efficacy.Depakine chrono can be easier to be absorbed than sustained-release agnesium proateet,butng-term effect on improving thect on improving the convulsive threshold is inferior to sustained-release magnesium valproate tablet.
机译:背景:学者们仅从药物科学或临床实践的角度研究了丙戊酸与其缓释片之间的药物代谢和药效学差异,不同剂量丙戊酸的药效和时效差异以及不同通过确定在确定直接皮层电刺激产生的惊厥阈值的大鼠模型中给药前和给药后惊厥阈值的变化,仍可以定量反映相同浓度的丙戊酸缓释片的类型。目的:本研究旨在通过确定直接皮层电刺激建立的大鼠模型的惊厥阈值和前后人血清药物浓度,比较丙戊酸镁,丙戊酸镁缓释片和地卡帕因chrono在癫痫治疗中的药效和时效行政管理N:一项受控的观察性实验。地点:山西医科大学癫痫研究所。材料:清洁级成年健康雄性SD大鼠,体重200-220 g,由山西医科大学实验动物中心提供。根据动物伦理委员会的指导要求,在湖南湘中药业有限公司生产丙戊酸镁(批号041004)和缓释丙戊酸镁片(批号050501)方法:本研究进行①于2005年6月至8月在山西医科大学癫痫实验室进行。①将所有SD大鼠制作为确定皮层惊厥阈的模型。将它们随机分为4组,每组20只大鼠:丙戊酸镁片剂组,维持-释放丙戊酸镁片剂组,去甲卡因地尼组和对照组。模拟后,对前三组的大鼠进行胃内注射镁分别以丙戊酸,丙戊酸缓释片和去甲卡地平为对照组,对照组给予相同体积的生理盐水灌胃。②每只空腹大鼠的惊厥阈值在0.5小时前测定,分别为0.5、1、2、3 ③单次给药后2周重复测定惊厥阈值。每只大鼠连续2次每天给药两次,惊厥阈值确定为0.5。③单次给药后分别于第4、5、6、7、8、9、10、12、14、24小时。 ④分别于给药前,给药后0.5小时,2.5小时,7小时和12小时。④给药1个月后收集肝,肾组织进行病理检查。⑤招募了9例健康的自愿性医疗药物。每个受试者均获得了书面知情同意书。该研究获得山西医科大学伦理委员会的批准。根据该计划,将9名志愿者随机分配到3个小组中。在空腹情况下,分别要求志愿者在早晨禁食条件下服用丙戊酸镁500克,丙戊酸缓释片500克和去甲卡因chrono 500克。通过荧光偏振测定每种药物的血清药物浓度主要观察指标:①单次,重复给药后大鼠惊厥阈值;②肝肾病理检查结果;③体内血清药物浓度。结果:①单次,反复给药后大鼠惊厥阈值:丙戊酸镁片的药效丙戊酸镁缓释片组和地帕金辛时效组均在单次给药后1〜2小时达到高峰,且在给药1小时后明显高于其他各组(P <0.05)。给药后7小时达到峰值,并且明显高于对照组。 p(P <0.05)。反复服用后,丙戊酸镁片组惊厥阈值的平均峰谷偏差为120-150Μa,分别是缓释丙戊酸镁片组和惊厥阈值的2和2.5倍。重复给药10次后,丙戊酸镁缓释片组的惊厥阈值较给药前增加440Μa,而去甲丙戊酸片剂组的惊厥阈值增加230μA。②肝,肾病理检查结果:连续给药1个月后,四组肝,肾功能损害无明显差异。③体内血清药物浓度:丙戊酸镁的血清药物浓度快速升高,达到峰值0.5-给药后2小时,给药后2-4小时保持相对稳定的水平结论:丙戊酸镁缓释片和去甲卡因chrono的药效在给药后1-6小时缓慢释放,在约7小时达到峰值,可持续约16小时。丙戊酸镁起效快,作用抵消。缓释丙戊酸镁片起效慢,但药效持续时间长。地帕金星比活泼丙酸阿替丁更容易被吸收,对改善治疗效果有长期作用在提高惊厥阈值方面不如持续释放丙戊酸镁片。

著录项

  • 来源
    《中国神经再生研究(英文版)》 |2007年第12期|732-735|共4页
  • 作者

  • 作者单位

    Research Institute of Epilepsy,Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;

    Research Institute of Epilepsy,Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;

    Research Institute of Epilepsy,Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;

    Research Institute of Epilepsy,Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 神经病学与精神病学;
  • 关键词

    epilepsy; valproate; convulsive threshold; serum drug concentration;

    机译:癫痫;丙戊酸盐;惊厥阈;血清药物浓度;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号